| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with …
Over the last 12 months, insiders at Actinium Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Actinium Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Actinium Pharmaceuticals, Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $4,372 was made by SETH SANDESH (Chairman & CEO) on 2018‑12‑10.
| 2018-12-10 | SETH SANDESH | Chairman & CEO | 10,000 0.0095% | $0.44 | $4,372 | -37.73% | ||
| 2018-12-10 | O'Loughlin Steve | Principal Financial Officer | 10,000 0.0095% | $0.43 | $4,350 | -37.73% | ||
| 2018-11-19 | Ludwig Dale L. | Chief Scientific Officer | 10,000 0.01% | $0.45 | $4,499 | -31.63% | ||
| 2018-07-17 | SETH SANDESH | CEO | 10,000 0.0094% | $0.79 | $7,900 | -28.76% | ||
| 2018-06-15 | O'Loughlin Steve | Principal Financial Officer | 12,000 0.0109% | $0.50 | $6,000 | +14.08% | ||
| 2018-04-19 | SETH SANDESH | Chairman & CEO | 5,000 0.0045% | $0.38 | $1,900 | +50.20% | ||
| 2018-02-28 | Shetty Ajit | director | 22,730 0.0257% | $0.43 | $9,774 | +25.81% | ||
| 2017-08-02 | SETH SANDESH | Chairman & CEO | 33,333 0.0538% | $0.75 | $25,000 | -3.30% | ||
| 2017-08-02 | Ray Nitya G. | Executive Vice President | 10,000 0.0161% | $0.75 | $7,500 | -3.30% | ||
| 2017-06-15 | SETH SANDESH | Chairman and CEO | 7,500 0.013% | $1.16 | $8,725 | -45.53% | ||
| 2017-06-15 | Berger Mark Stanley | Chief Medical Officer | 5,000 0.0083% | $1.11 | $5,550 | -45.53% | ||
| 2017-06-15 | O'Loughlin Steve | Principal Financial Officer | 3,500 0.0061% | $1.17 | $4,095 | -45.53% | ||
| 2016-12-30 | SETH SANDESH | Executive Chairman | 5,000 0.0104% | $0.88 | $4,400 | +16.57% | ||
| 2016-12-12 | SETH SANDESH | Executive Chairman | 5,000 0.0104% | $0.98 | $4,900 | +5.15% | ||
| 2016-08-31 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 136,853 0.2928% | $1.83 | $251,118 | -34.31% | |
| 2016-08-30 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 56,074 0.1174% | $1.81 | $101,254 | -33.90% | |
| 2016-08-29 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 25,000 0.0529% | $1.72 | $42,875 | -28.89% | |
| 2016-08-26 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 25,000 0.052% | $1.70 | $42,620 | -29.07% | |
| 2016-08-16 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 5,029 0.0107% | $1.72 | $8,652 | -26.18% | |
| 2016-08-15 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 4,439 0.0093% | $1.72 | $7,635 | -25.87% |
| SETH SANDESH | Chairman & CEO | 153333 0.4877% | $214,666.20 | 10 | 0 | <0.0001% |
| DAVE KAUSHIK J | CEO and Interim CFO | 88500 0.2815% | $123,900.00 | 1 | 0 | <0.0001% |
| O'Loughlin Steve | Principal Financial Officer | 35500 0.1129% | $49,700.00 | 3 | 0 | <0.0001% |
| Shetty Ajit | director | 22730 0.0723% | $31,822.00 | 1 | 0 | +25.81% |
| Nicholson, C. David | director | 15000 0.0477% | $21,000.00 | 1 | 0 | <0.0001% |
| Ray Nitya G. | Executive Vice President | 10000 0.0318% | $14,000.00 | 1 | 0 | <0.0001% |
| Ludwig Dale L. | Chief Scientific Officer | 10000 0.0318% | $14,000.00 | 1 | 0 | <0.0001% |
| Berger Mark Stanley | Chief Medical Officer | 5000 0.0159% | $7,000.00 | 1 | 0 | <0.0001% |
| TRAVERSA SERGIO | director | 3000 0.0095% | $4,200.00 | 2 | 0 | <0.0001% |
| Steinhart Richard I | director | 2500 0.008% | $3,500.00 | 1 | 0 | <0.0001% |
| MAZANET ROSEMARY | director | 100 0.0003% | $140.00 | 1 | 0 |
$2,542,362 | 111 | 11.81% | $36.83M | |
$156,891,025 | 80 | -24.91% | $36.3M | |
$84,911,583 | 59 | 17.82% | $37.44M | |
$693,326 | 47 | -16.24% | $40.24M | |
$6,204,522 | 45 | 1.91% | $36.5M |
| Increased Positions | 22 | +28.95% | 583,760 | +11.28% |
| Decreased Positions | 28 | -36.84% | 322,519 | -6.23% |
| New Positions | 9 | New | 282,521 | New |
| Sold Out Positions | 8 | Sold Out | 173,636 | Sold Out |
| Total Postitions | 70 | -7.89% | 5M | +5.05% |
| Vanguard Group Inc | $1,897.00 | 4.47% | 1.38M | +12,703 | +0.93% | 2025-09-30 |
| Millennium Management Llc | $856.00 | 2.02% | 624,697 | -38,572 | -5.82% | 2025-09-30 |
| Acadian Asset Management Llc | $671.00 | 1.58% | 489,577 | -2,366 | -0.48% | 2025-09-30 |
| Blackrock, Inc. | $498.00 | 1.17% | 363,486 | -104,187 | -22.28% | 2025-09-30 |
| Geode Capital Management, Llc | $450.00 | 1.06% | 328,419 | -1,270 | -0.39% | 2025-09-30 |
| Renaissance Technologies Llc | $395.00 | 0.93% | 288,630 | +79,129 | +37.77% | 2025-09-30 |
| Two Sigma Investments, Lp | $321.00 | 0.76% | 234,293 | +187,748 | +403.37% | 2025-09-30 |
| Gagnon Securities Llc | $310.00 | 0.73% | 226,257 | -365 | -0.16% | 2025-09-30 |
| Two Sigma Advisers, Lp | $269.00 | 0.63% | 196,376 | +196,376 | New | 2025-09-30 |
| Citadel Advisors Llc | $173.00 | 0.41% | 126,615 | +71,609 | +130.18% | 2025-09-30 |